UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters

Journal of the National Cancer Institute

Volumn 99, Issue 17, 2007, Pages 1290-1295

  Hoskins, Janelle M ^a,b   Goldberg, Richard M ^a,c   Qu, Pingping ^d   Ibrahim, Joseph G ^b,d   McLeod, Howard L ^a,b,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; LYMPHOMA; METASTASIS; MONOTHERAPY; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SINGLE DRUG DOSE; SOLID TUMOR; DOSE RESPONSE; GENETICS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS;

EID: 34548598459     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm115     Document Type: Article

References (19)

1. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004;5:835-43.
2. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci USA 1998; 95:8170-4.
3. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-7.
4. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22: 1382-8.
5. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004;44:854-60.
6. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004;91:678-82.
7. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-9.
8. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000;60:6921-6.
9. Hasegawa Y, Sarashina T, Ando M, Kitagawa C, Mori A, Yoneyama M, et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem 2004;50:1479-80.
10. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106:1007-16.
11. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005;11:1226-36.
12. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061-8.
13. Chiara S, Serra M, Marroni P, Lastraioli S, Ponzanelli A, Tomasello L, et al. UGT1A1 promoter genotype and toxicity in patients with advanced colorectal cancer treated with irinotecan-containing chemotherapy. In. Journal of Clinical Oncology ASCO Annual Meeting Proceedings 2005; 2005:2016.
14. McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. In: Journal of Clinical Oncology ASCO Annual Meeting Proceedings 2006; 2006:3520.
15. Font A, Sanchez JM, Taron M, Martinez-Balibrea E, Sanchez JJ, Manzano JL, et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 2003;21:435-43.
16. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001;358: 1356-60.
17. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006; 24:3347-53.
18. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: Lessons learned. Pharmacogenet Genomics 2006; 16:847-54.
19. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 2006; 24:3347-53.